News & Updates

2809, 2019

Agendia Presents New Data on the Biological Characteristics of Patients within Extreme Low Risk and High Risk MammaPrint Subgroups at the European Society for Medical Oncology (ESMO)

September 28th, 2019|

  PRESS RELEASE IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – 29 September 2019 – Agendia, Inc., a world leader in precision oncology for breast cancer, will present new data from their on-going clinical research at Read More

2006, 2019

Agendia Announces Publication of Study Validating Use of MammaPrint and BluePrint Molecular Diagnostics using Targeted RNA Next-Generation Sequencing Technology

June 20th, 2019|

  PRESS RELEASE IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – 20 June 2019 – Agendia, Inc., a world leader in precision oncology, announced today the open access publication of MammaPrint and BluePrint Molecular Diagnostics using Read More